How big is the GLP-1 market? Exploring its growth potential By
GLP-1 receptor agonists are changing the way chronic conditions like type 2 diabetes are managed, but they have also been approved in the United States to treat obesity, resulting in investors assessing the various outcomes if they become more widely adopted. But how big is the market for these…#glp1 #goldmansachs #fatimacodystanford #glp1s #mit #jonathangruber #novonordiskas #medicare #goldman #biotech (Source: Reuters: Health)
Source: Reuters: Health - April 15, 2024 Category: Consumer Health News Source Type: news
HbA1c test may be inaccurate for thousands of South Asian people, research finds
Tens of thousands of people of South Asian heritage with diabetes and pre-diabetes may have underestimated HbA1c levels researchers have said, after they identified a genetic variant that affects the accuracy of the test. (Source: GP Online News)
Source: GP Online News - April 15, 2024 Category: Primary Care Tags: Clinical News Source Type: news
Obesity: Improving Communication About a Sensitive Topic Obesity: Improving Communication About a Sensitive Topic
An endocrinologist and her patient share thoughts on improving communication about obesity and the importance of shared decision-making in weight reduction strategies.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 15, 2024 Category: Consumer Health News Tags: Diabetes & Endocrinology Care Cues Source Type: news
Novo Nordisk Arms Wegovy to Be a Triple Threat
Ozempic usage for weight loss has gone viral, making it the highest revenue-generating drug for Novo Nordisk AV/S NYSE: NVO. Originally purposed for Type 2 diabetes, the skyrocketing off-label use for weight loss led Novo to create Wegovy, a stronger version of Ozempic (generic name: semaglutide)…#novonordiskavsnyse #nvo #novo #ozempic #glp1 #elylillyco #lly #novonordisk #ejectionfraction #bmi (Source: Reuters: Health)
Source: Reuters: Health - April 15, 2024 Category: Consumer Health News Source Type: news
More Than 250 Websites Selling Fake Weight-loss Drugs Reported by Anti-counterfeit Firm More Than 250 Websites Selling Fake Weight-loss Drugs Reported by Anti-counterfeit Firm
The cybersecurity firm BrandShield has taken down more than 250 websites selling fake versions of popular weight-loss and diabetes drugs in the GLP-1 class, the company ’s...Reuters Health Information (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - April 15, 2024 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news
The effects of vibrating shoe insoles on standing balance, walking, and ankle-foot muscle activity in adults with diabetic peripheral neuropathy - Hatton AL, Chatfield MD, Cattagni T, Vicenzino B.
BACKGROUND: Peripheral neuropathy is one of the most common complications of type 2 diabetes, which can lead to impaired balance and walking. Innovative footwear devices designed to stimulate foot sensory receptors, such as vibrating insoles, could offer a... (Source: SafetyLit)
Source: SafetyLit - April 15, 2024 Category: International Medicine & Public Health Tags: Engineering, Physics, Structural Soundness and Failure Source Type: news
Childhood maltreatment and the risk of impaired glucose metabolism or type 2 diabetes in young adults: findings from the Lifelines Cohort Study - Desch ênes SS, Nearchou F, McInerney A, Schmitz N, Pouwer F, Nouwen A.
We examined the associations between childhood maltreatment and the risk of impaired glucose metabolism (IGM) or type 2 diabetes (T2D) in young adults aged 18-35. Participants (N = 8506) from the Lifelines Cohort Study without IGM or diabetes at baseline (... (Source: SafetyLit)
Source: SafetyLit - April 15, 2024 Category: International Medicine & Public Health Tags: Age: Adolescents Source Type: news
Diabetes symptom warning as pharmacist reveals five signs to watch out for
Pharmacist Graham Phillips is warning that the obesity epidemic is leading to a surge in prediabetes numbers. (Source: Daily Express - Health)
Source: Daily Express - Health - April 15, 2024 Category: Consumer Health News Source Type: news
Know the signs of irritable bowel syndrome
April is IBS Awareness Month, which makes this a good time to learn about the symptoms of irritable bowel syndrome, or IBS. Research suggests that about 12% of people in the U.S. have irritable bowel syndrome, and it's more common among women than men and in people younger than 50, according to the National Institute of Diabetes and Digestive and Kidney Diseases. Irritable bowel syndrome is a chronic condition that affects the large intestine. Even though the digestive… (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - April 14, 2024 Category: Databases & Libraries Source Type: news
No link between Ozempic, Wegovy and suicide, EU drug regulators say
Drug regulators in Europe have found no evidence that popular diabetes and weight-loss drugs like Ozempic and Wegovy are linked to a higher risk of suicidal thoughts or actions (Source: ABC News: Health)
Source: ABC News: Health - April 12, 2024 Category: Consumer Health News Tags: Health Source Type: news
ESG More Cost-Effective Long Term Than Semaglutide ESG More Cost-Effective Long Term Than Semaglutide
Semaglutide is an effective treatment option for weight loss, but its cost-effectiveness over the long term compared with ESG needs to be considered.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - April 12, 2024 Category: Endocrinology Tags: Diabetes & Endocrinology Clinical Summary Source Type: news
Semaglutide Benefits in HFpEF Step Beyond Weight Loss Semaglutide Benefits in HFpEF Step Beyond Weight Loss
Drs Pi ña and Kosiborod discuss semaglutide in obesity-related HF with and without diabetes. Both STEP HFpEF trials show similar HF benefits despite less weight loss in patients with diabetes.theheart.org on Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - April 12, 2024 Category: Cardiology Tags: Cardiology Commentary Source Type: news
Diabetes drug shows potential in treating Parkinson ’s disease
A medicine for type 2 diabetes may slow the progression of the symptoms of Parkinson’s disease, research has suggested. Investigators evaluating the glucagon-like peptide 1 receptor agonist (GLP-1 RA) lixisenatide reported less progression of motor disability over a 12-month period in patients taking the drug compared with placebo. But writing in the New England Journal of Medicine, they... Read moreThe post Diabetes drug shows potential in treating Parkinson’s disease appeared first on Nursing in Practice. (Source: Nursing in Practice)
Source: Nursing in Practice - April 12, 2024 Category: Nursing Authors: Megan Ford Tags: Clinical Diabetes Latest news Source Type: news
Factors Affecting Postexercise Glycemia in Youth With T1D Factors Affecting Postexercise Glycemia in Youth With T1D
Insights into factors affecting postexercise glucose fluctuations in adolescents with T1D could shape new guidelines and decision support tools.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - April 12, 2024 Category: Endocrinology Tags: Diabetes & Endocrinology Clinical Summary Source Type: news
GLP-1 Receptor Agonists Don't Raise Thyroid Cancer Risk GLP-1 Receptor Agonists Don't Raise Thyroid Cancer Risk
A cohort study in three Scandinavian countries found no significant increase in thyroid cancer risk with glucagon-like peptide 1 receptor agonists.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - April 12, 2024 Category: Endocrinology Tags: Diabetes & Endocrinology Clinical Summary Source Type: news
